NL-OMON47050撤回4 期
Pharmacokinetics of single-dose dOLutegravir in HIV-serOnegative sub-jects with severe hepatic impairment compared to matched controls (POLO). - POLO
Afdeling Apotheek0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Hepatic impairment group:
- •1. Subject is at least 18 and not older than 90 years at screening.
- •2. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- •3. Child-Pugh score 10 or greater (Appendix A). Expected to be in clinical stable condition for at least 4 weeks as assessed by the subject*s own hepatologist. This assessment takes into account the following aspects: MELD score, fibroscan results (if available), life expectancy, recent history of decompensation events and the rate of progression of hepatic insufficiency.;Matched controls:
- •1. Subject is at least 18 and not older than 90 years at screening.
- •2. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- •3. Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to Day 1. Results of biochemistry, haematology and urinalysis testing should be within the laboratory's reference ranges (see Appendix D). If laboratory results are not within the reference ranges, the subject is in-cluded on condition that the Investigator judges that the deviations are not clinically relevant. This should be clearly recorded.
- •4. Subject has a normal blood pressure and pulse rate, according to the Investigator's judgement.
排除标准
- •Hepactic impairment group:
- •1. Inability to understand the nature and extent of the study and the pro-cedures required.
- •2. Gilbert*s syndrome or other underlying disease (other than hepatic impairment) that causes alterations in the Child-Pugh class components (bilirubin, albumin, protombin, encephalopathy and ascites).
- •3. Therapy with strong inducers or inhibitors of UGT1A1 or drugs that are contra-indicated with concomitant use of dolutegravir (see appendix B). (NB. there are restrictions for intake of magnesium/aluminium-containing antacids, iron and calcium supplements, multivitamins and other cation-containing supplements.
- •4. Positive HIV test.
- •5. Participation in a drug study within 60 days prior to Day 1.
- •6. Febrile illness within 3 days before Day 1.;Matched controls:
- •1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
- •2. Positive HIV test.
- •3. Positive hepatitis B or C test.
- •4. Pregnant female (as confirmed by an hCG test performed less than 4 weeks before Day 1) or breast-feeding female. Female subjects of childbearing potential without adequate contraception (see Appendix C).
- •5. Therapy with strong inducers or inhibitors of UGT1A1 or drugs that are contra-indicated with concomitant use of dolutegravir (see appendix B). (NB. there are restrictions for intake of magnesium/aluminium-containing antacids, iron- and calciumsupplements, multivitamins and other cation-containing supplements.
- •6. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), psychiatric disorders, gastro-intestinal disor-ders, renal and hepatic disorders, hormonal disorders (especially dia-betes mellitus), coagulation disorders.
- •7. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- •8. History of or current abuse of drugs, alcohol or solvents.
- •9. Inability to understand the nature and extent of the study and the pro-cedures required.
- •10. Participation in a drug study within 60 days prior to Day 1.
- •11. Donation of blood within 60 days prior to Day 1.
- •12. Febrile illness within 3 days before Day 1
- •13. UGT1A1 polymorphism (at least one *28, *37 or *6 allele)
研究者
相似试验
撤回
4 期
Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.HIV-1-infectionHepatic ImpairmentNCT03813979Radboud University Medical Center
尚未招募
Unknown
In vivo Bioequivalence study of Dolutegravir tabletsIRCT20220211053992N36Tabriz University of Medical Sciences24
尚未招募
Unknown
Benefits and safety of major medicines in HIV patients.CTRI/2024/04/065522Institute of Medical Sciences, Banaras Hindu University
招募中
2 期
Evaluation of the effect of an antiretroviral drug in patients infected with HTLV-1.Human T-lymphotropic virus 1B04RBR-5x7ccxpFundação Bahiana de Infectologia - FBA
已完成
1 期
A Phase I Single Dose Pharmacokinetic Study of DG17 versus DG17 in combination with ritonavir in Healthy SubjectsHealthy subjectsOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)ACTRN12606000154505arhex Life Sciences Ltd.18